Viatris: Watch Out For Potential Complex Injectable Launches In 2023

As Firm Welcomes Generics ‘Momentum We Have Never Seen Before’

Viatris has again the lauded the potential of its complex injectables and steriles pipeline, as it looks to build a business generating revenues of up to $1bn per year within the next five years.

NWW Binoculaurs
• Source: Shutterstock

Viatris has guided for certain of its pipeline of complex injectable and sterile products in the US to come to market “if we are optimistic later this year or early next year,” as it continues to aim towards building a franchise worth, it believes, at least $1bn per year in peak net sales by 2027 or 2028.

The company has eight first-to-market opportunities that are currently under regulatory review from within its complex injectable/steriles pipeline, including a...

More from Earnings

More from Business